Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis.

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

After doctor’s office visits for flu dipped early this year, they jumped past the previous season peak at the end of last ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

The Chancellor is under political pressure because of a lack of growth and related fear of a recession caused by her Budget, ...

Bose, 54, promised a junior colleague more money for a 'couple of hours' work than he would make in a month if she went along ...

A Georgia sculptor gave birth during the coronavirus pandemic. Five years later, she is designing a monument honoring those who have died with COVID-19.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...